CAMP4 Therapeutics Corp banner

CAMP4 Therapeutics Corp
NASDAQ:CAMP

Watchlist Manager
CAMP4 Therapeutics Corp Logo
CAMP4 Therapeutics Corp
NASDAQ:CAMP
Watchlist
Price: 4.65 USD 3.56% Market Closed
Market Cap: $241.4m

Multiples-Based Value

The Multiples-Based Value for CAMP4 Therapeutics Corp (CAMP) under the Base Case is hidden USD. Compared with the current market price of 4.65 USD, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAMP Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

CAMP Competitors Multiples
CAMP4 Therapeutics Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CAMP4 Therapeutics Corp
NASDAQ:CAMP
241.8m USD 69.1 -3 -4.8 -4.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
364.8B USD 6 87.2 14.5 20.1
US
Amgen Inc
NASDAQ:AMGN
183.3B USD 5 23.7 13.8 13.8
US
Gilead Sciences Inc
NASDAQ:GILD
172.3B USD 5.9 20.3 12.7 15.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.7B USD 9.1 27.7 20.8 21.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.4B USD 5.6 17.8 13.3 15.2
AU
CSL Ltd
ASX:CSL
67.6B AUD 3 33.6 11.3 14.2
NL
argenx SE
XBRU:ARGX
39.7B EUR 11.6 37.3 40.7 41.5
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
CAMP4 Therapeutics Corp
NASDAQ:CAMP
Average P/S: 3 063 009
69.1
53%
1.3
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.1
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3
4%
0.8
NL
argenx SE
XBRU:ARGX
11.6
28%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
CAMP4 Therapeutics Corp
NASDAQ:CAMP
Average P/E: 35.4
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.2
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.7
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.3
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
AU
CSL Ltd
ASX:CSL
33.6
10%
3.4
NL
argenx SE
XBRU:ARGX
37.3
32%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
CAMP4 Therapeutics Corp
NASDAQ:CAMP
Average EV/EBITDA: 18.1
Negative Multiple: -4.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.5
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.8
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.8
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
NL
argenx SE
XBRU:ARGX
40.7
50%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
CAMP4 Therapeutics Corp
NASDAQ:CAMP
Average EV/EBIT: 20.3
Negative Multiple: -4.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.1
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
13.8
3%
4.6
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
NL
argenx SE
XBRU:ARGX
41.5
51%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett